

Lisi Flores Aguilar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6205988/publications.pdf>

Version: 2024-02-01

97
papers

5,965
citations

70961

41
h-index

76769

74
g-index

101
all docs

101
docs citations

101
times ranked

6760
citing authors

#	ARTICLE	IF	CITATIONS
1	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1917-1933.	3.7	1,008
2	Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6735-6740.	3.3	312
3	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	2.2	201
4	Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes. <i>Journal of Neuroscience</i> , 1999, 19, 2706-2716.	1.7	193
5	The anatomy of the CNS cholinergic neurons. <i>Trends in Neurosciences</i> , 1984, 7, 74-78.	4.2	187
6	Modeling Alzheimer's disease in transgenic rats. <i>Molecular Neurodegeneration</i> , 2013, 8, 37.	4.4	144
7	Depletion of substance P-containing axons in substantia gelatinosa of patients with diminished pain sensitivity. <i>Nature</i> , 1982, 295, 61-63.	13.7	132
8	Choline acetyltransferase-immunoreactive profiles are presynaptic to primary sensory fibers in the rat superficial dorsal horn. <i>Journal of Comparative Neurology</i> , 1990, 295, 370-384.	0.9	131
9	Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1309-1318.	0.9	130
10	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 338-348.	4.0	127
11	Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2249-2262.	1.5	123
12	Amyloid β -Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 857-869.	0.9	122
13	Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 956-966.	4.0	119
14	Paradoxical Upregulation of Glutamatergic Presynaptic Boutons during Mild Cognitive Impairment. <i>Journal of Neuroscience</i> , 2007, 27, 10810-10817.	1.7	117
15	Cholinergic Involvement in Alzheimer's Disease. A Link with NGF Maturation and Degradation. <i>Journal of Molecular Neuroscience</i> , 2010, 40, 230-235.	1.1	111
16	Immunohistochemical demonstration of some putative neurotransmitters in the lamprey spinal cord and spinal ganglia: 5-hydroxytryptamine-, tachykinin-, and neuropeptide-Y-immunoreactive neurons and fibers. <i>Journal of Comparative Neurology</i> , 1985, 234, 501-522.	0.9	105
17	Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. <i>Journal of Neuroinflammation</i> , 2012, 9, 62.	3.1	89
18	Intracellular $A\beta$ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. <i>Acta Neuropathologica Communications</i> , 2014, 2, 61.	2.4	84

#	ARTICLE	IF	CITATIONS
19	Impact of the NGF Maturation and Degradation Pathway on the Cortical Cholinergic System Phenotype. <i>Journal of Neuroscience</i> , 2012, 32, 2002-2012.	1.7	83
20	5-Hydroxytryptamine, substance P, and thyrotropin-releasing hormone in the adult cat spinal cord segment L7: Immunohistochemical and chemical studies. <i>Synapse</i> , 1990, 6, 237-270.	0.6	79
21	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
22	Nerve growth factor metabolic dysfunction in Down syndrome brains. <i>Brain</i> , 2014, 137, 860-872.	3.7	75
23	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. <i>Alzheimer's and Dementia</i> , 2016, 12, 1132-1148.	0.4	75
24	eIF2 \pm controls memory consolidation via excitatory and somatostatin neurons. <i>Nature</i> , 2020, 586, 412-416.	13.7	74
25	The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology. <i>Frontiers in Neuroscience</i> , 2019, 13, 62.	1.4	73
26	Intracellular and Extracellular A β ² , a Tale of Two Neuropathologies. <i>Brain Pathology</i> , 2005, 15, 66-71.	2.1	66
27	The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer's Disease. <i>Neurochemical Research</i> , 2007, 32, 1041-1045.	1.6	66
28	Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2017, 108, 307-323.	2.1	66
29	Evidence of intraneuronal A β ² accumulation preceding tau pathology in the entorhinal cortex. <i>Acta Neuropathologica</i> , 2018, 136, 901-917.	3.9	65
30	Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6844-6854.	3.3	62
31	Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 321.	1.0	61
32	Connecting the dots: From Free Radical Lipid Autoxidation to Cell Pathology and Disease. <i>Chemical Reviews</i> , 2020, 120, 12757-12787.	23.0	61
33	Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. <i>Brain</i> , 2020, 143, 3653-3671.	3.7	59
34	NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo. <i>Neurobiology of Disease</i> , 2018, 114, 24-30.	2.1	58
35	A β ² -induced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , 2019, 10, 2353.	5.8	58
36	The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2015, 13, 53-67.	0.7	57

#	ARTICLE	IF	CITATIONS
37	A β Immunoreactive Material Is Present in Several Intracellular Compartments in Transfected, Neuronally Differentiated, P19 Cells Expressing the Human Amyloid β -Protein Precursor. <i>Journal of Alzheimer's Disease</i> , 2000, 2, 207-222.	1.2	56
38	Peripheral nerve injury leads to the establishment of a novel pattern of sympathetic fibre innervation in the rat skin. , 2000, 422, 287-296.		56
39	Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 667-678.	1.2	55
40	Reimagining cholinergic therapy for Alzheimer's disease. <i>Brain</i> , 2022, 145, 2250-2275.	3.7	50
41	Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model. <i>Scientific Reports</i> , 2016, 6, 34051.	1.6	49
42	Ectopic Substance P and Calcitonin Gene-related Peptide Immunoreactive Fibres in the Spinal Cord of Transgenic Mice Over-expressing Nerve Growth Factor. <i>European Journal of Neuroscience</i> , 1995, 7, 2021-2035.	1.2	47
43	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. <i>Journal of Neuroscience</i> , 2017, 37, 12263-12271.	1.7	44
44	Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 69-84.	2.4	40
45	The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. <i>Molecular Psychiatry</i> , 2021, 26, 6023-6037.	4.1	40
46	Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease. <i>Cerebral Cortex</i> , 2016, 27, 1501-1511.	1.6	39
47	AF710B, an M1/ σ_1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 811-823.	0.4	39
48	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. <i>Trends in Neurosciences</i> , 2014, 37, 629-641.	4.2	38
49	Perturbed mitochondria-ER contacts in live neurons modelling Alzheimer's disease amyloid pathology. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	35
50	NPO3, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 723-739.	1.2	33
51	Chapter 32: Trophic responses of forebrain cholinergic neurons: a discussion. <i>Progress in Brain Research</i> , 1993, 98, 265-277.	0.9	32
52	Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 327-341.	1.2	32
53	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. <i>NeuroMolecular Medicine</i> , 2021, 23, 561-571.	1.8	30
54	Worsening of memory deficit induced by energy-dense diet in a rat model of early-Alzheimer's disease is associated to neurotoxic Al ²⁺ species and independent of neuroinflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 731-743.	1.8	28

#	ARTICLE	IF	CITATIONS
55	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5989-6001.	4.1	28
56	Hippocampal hyperactivity in a rat model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2021, 157, 2128-2144.	2.1	28
57	Light and electron microscopic study of the distribution of substance P-immunoreactive fibers and neurokinin-1 receptors in the skin of the rat lower lip. <i>Journal of Comparative Neurology</i> , 2001, 432, 466-480.	0.9	27
58	Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. <i>Neurobiology of Aging</i> , 2018, 67, 10-20.	1.5	27
59	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	2.0	27
60	Targeting glutamatergic and cellular prion protein mechanisms of amyloid β -mediated persistent synaptic plasticity disruption: Longitudinal studies. <i>Neuropharmacology</i> , 2017, 121, 231-246.	2.0	26
61	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 621440.	2.2	26
62	Ultrastructural and neurochemical analysis of synaptic input to trigemino-thalamic projection neurones in lamina I of the rat: A combined immunocytochemical and retrograde labelling study. <i>Journal of Comparative Neurology</i> , 1989, 285, 467-486.	0.9	21
63	Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. <i>Molecular Neurobiology</i> , 2018, 55, 3451-3476.	1.9	21
64	The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 373-383.	1.2	19
65	Similarities in the ultrastructural distribution of nerve growth factor receptor-like immunoreactivity in cerebellar Purkinje cells of the neonatal and colchicine-treated adult rat. <i>Journal of Comparative Neurology</i> , 1991, 305, 189-200.	0.9	18
66	Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer's-like Amyloidosis. <i>Current Alzheimer Research</i> , 2018, 15, 1220-1230.	0.7	18
67	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021, 17, 605-617.	0.4	17
68	The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. <i>Cells</i> , 2022, 11, 16.	1.8	17
69	A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2021, 148, 105150.	2.1	16
70	Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. <i>European Journal of Pharmacology</i> , 2017, 817, 7-19.	1.7	15
71	Cellular and subcellular localization of nerve growth factor receptor-like immunoreactivity in the rat CNS. <i>Neurochemistry International</i> , 1990, 17, 205-213.	1.9	14
72	Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. <i>Neurobiology of Disease</i> , 2019, 127, 323-338.	2.1	14

#	ARTICLE	IF	CITATIONS
73	Localization of Substance P in Neuronal Pathways. Novartis Foundation Symposium, 1982, , 55-83.	1.2	14
74	Hemicholinium mustard derivatives: Preliminary assesment of cholinergic neurotoxicity. Neurochemical Research, 1986, 11, 1091-1102.	1.6	13
75	Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models. Life Sciences, 2012, 91, 1141-1147.	2.0	13
76	Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease. Frontiers in Pharmacology, 2019, 10, 189.	1.6	13
77	Chronic Hippocampal Expression of Notch Intracellular Domain Induces Vascular Thickening, Reduces Glucose Availability, and Exacerbates Spatial Memory Deficits in a Rat Model of Early Alzheimer. Molecular Neurobiology, 2018, 55, 8637-8650.	1.9	12
78	Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition. Journal of Neuroinflammation, 2021, 18, 147.	3.1	11
79	Impact of Intracellular A β -Amyloid in Transgenic Animals and Cell Models. Neurodegenerative Diseases, 2008, 5, 146-148.	0.8	10
80	Effect of antioxidant supplements on lipid peroxidation levels in primary cortical neuron cultures. Free Radical Biology and Medicine, 2019, 130, 471-477.	1.3	10
81	Gangliosides, NGF, Brain Aging and Disease: A Mini-Review with Personal Reflections. Neurochemical Research, 2012, 37, 1256-1260.	1.6	9
82	Early Long-Term Memory Impairment and Changes in the Expression of Synaptic Plasticity-Associated Genes, in the McGill-R-Thy1-APP Rat Model of Alzheimer's-Like Brain Amyloidosis. Frontiers in Aging Neuroscience, 2020, 12, 585873.	1.7	9
83	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 788-801.	2.4	8
84	Role of Immunology in Defining Transmitter-Specific Neurons. Immunological Reviews, 1987, 100, 279-306.	2.8	7
85	Platelets Bioenergetics Screening Reflects the Impact of Brain A β Plaque Accumulation in a Rat Model of Alzheimer. Neurochemical Research, 2019, 44, 1375-1386.	1.6	7
86	mTORC2 mediates structural plasticity in distal nociceptive endings that contributes to pain hypersensitivity following inflammation. Journal of Clinical Investigation, 2022, 132, .	3.9	6
87	Choline Acetyltransferase Activity in the Rat Trigeminal System. Journal of Neurochemistry, 1985, 45, 1027-1029.	2.1	4
88	Editorial: The Involvement of NGF in the Alzheimer's Pathology. Frontiers in Neuroscience, 2019, 13, 872.	1.4	4
89	The Pharmacology of Neurotrophic Factors. , 1995, , 241-254.		4
90	Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	4

#	ARTICLE	IF	CITATIONS
91	[No Title]. British Journal of Psychiatry, 1993, 163, 693-694.	1.7	3
92	Editorial: Tau Pathology in Neurological Disorders. Frontiers in Neurology, 2021, 12, 754669.	1.1	2
93	Rita Levi-Montalcini, NGF Metabolism in Health and in the Alzheimer's Pathology. Advances in Experimental Medicine and Biology, 2021, 1331, 119-144.	0.8	2
94	What's new: Hybridoma technology in immunocytochemistry. BioEssays, 1984, 1, 178-179.	1.2	1
95	Leslie Iversen, a friend of friends and an inspiring light in neuropharmacology. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	1
96	Nerve Growth Factor Compromise in Down Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 719507.	1.7	1
97	Ted Sourkes, Moussa Youdim and I. Journal of Neural Transmission, 2020, 127, 119-123.	1.4	0